Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
- Conditions
- VancomycinStaphylococcal InfectionsAdverse EffectAcute Kidney InjuryCross-sectional Study
- Interventions
- Registration Number
- NCT03456544
- Lead Sponsor
- Peking University First Hospital
- Brief Summary
The objective of this study was to investigate the current situation of vancomycin (VAN)-associated acute kidney injury (VA-AKI) in China and identify the risk factors for VA-AKI, as well as to comprehensively examine the risk related to concurrent drug use. Further, the investigators assessed the outcomes of patients who developed VA-AKI and the risk factors for these outcomes. Finally, the investigators aimed to provide suggestions for improving the prevention and treatment of VA-AKI in China.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10000
Inclusion Criteria
- Using Vancomycin
- ≥18 years old
Exclusion Criteria
- Medical records were incomplete
- Had been diagnosed with stage 5 CKD or were regularly receiving dialysis
- SCr were not being adequately monitored to detect the development of AKI
- Had undergone nephrectomy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description VAN-AKI Vancomycin Patients who had vancomycin associated acute kidney injury.
- Primary Outcome Measures
Name Time Method Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate 1 year
- Secondary Outcome Measures
Name Time Method VAN-AKI detection rate 1 year TDM detction rate 1 year 0h Serum creatinine detction rate 1 year 48h Serum creatinine detction rate 1 year
Trial Locations
- Locations (1)
Peking University First Hospital
🇨🇳Beijing, Beijing, China